Discovery Laboratories said Monday the Food and Drug Administration wants even more information for the company's new drug application on Surfaxin, designed to prevent respiratory distress in premature infants. This is the FDA's second request for more information from Discovery. If approved, Surfaxin would be Discovery's first product to reach market.
- read this story from the Philadelphia Business Journal for more